Elsa V Arocho-Quinones1, Sean M Lew1,2, Michael H Handler3, Zulma Tovar-Spinoza4, Matthew Smyth5, Robert Bollo6, David Donahue7, M Scott Perry8, Michael L Levy9, David Gonda9, Francesco T Mangano10, Phillip B Storm11, Angela V Price12, Daniel E Couture13, Chima Oluigbo14, Ann-Christine Duhaime15, Gene H Barnett16, Carrie R Muh17, Michael D Sather18, Aria Fallah19, Anthony C Wang19, Sanjiv Bhatia20, Kadam Patel21, Sergey Tarima21, Sarah Graber3, Sean Huckins4, Daniel M Hafez5, Kavelin Rumalla5, Laurie Bailey7, Sabrina Shandley7, Ashton Roach10, Erin Alexander11, Wendy Jenkins13, Deki Tsering14, George Price15, Antonio Meola16, Wendi Evanoff16, Eric M Thompson17, Nicholas Brandmeir18. 1. 1Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. 2Department of Neurosurgery, Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 3. 3Department of Neurosurgery, Children's Hospital Colorado, Aurora, Colorado. 4. 4Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, New York. 5. 5Department of Neurosurgery, St. Louis Children's Hospital, St. Louis, Missouri. 6. 6Department of Neurosurgery, Primary Children's Hospital, Salt Lake City, Utah. 7. Departments of7Neurosurgery and. 8. 8Neurology, Cook Children's Hospital, Fort Worth, Texas. 9. 9Department of Neurosurgery, Rady Children's Hospital-San Diego, California. 10. 10Department of Neurosurgery, Cincinnati Children's Hospital, Cincinnati, Ohio. 11. 11Department of Neurosurgery, Children's Hospital of Philadelphia, Pennsylvania. 12. 12Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas, Texas. 13. 13Department of Neurosurgery, Wake Forest Baptist Health, Winston-Salem, North Carolina. 14. 14Department of Neurosurgery, Children's National Health System, Washington, DC. 15. 15Department of Neurosurgery, Massachusetts General Hospital for Children, Boston, Massachusetts. 16. 16Department of Neurosurgery, Cleveland Clinic Children's, Cleveland, Ohio. 17. 17Department of Neurosurgery, Duke Children's Hospital, Durham, North Carolina. 18. 18Department of Neurosurgery, Penn State Health, Hershey, Pennsylvania. 19. 19Department of Neurosurgery, UCLA Mattel Children's Hospital, Los Angeles, California. 20. 20Department of Neurosurgery, Nicklaus Children's Hospital, Miami, Florida; and. 21. 21Department of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract
OBJECTIVE: This study aimed to assess the safety and efficacy of MR-guided stereotactic laser ablation (SLA) therapy in the treatment of pediatric brain tumors. METHODS: Data from 17 North American centers were retrospectively reviewed. Clinical, technical, and radiographic data for pediatric patients treated with SLA for a diagnosis of brain tumor from 2008 to 2016 were collected and analyzed. RESULTS: A total of 86 patients (mean age 12.2 ± 4.5 years) with 76 low-grade (I or II) and 10 high-grade (III or IV) tumors were included. Tumor location included lobar (38.4%), deep (45.3%), and cerebellar (16.3%) compartments. The mean follow-up time was 24 months (median 18 months, range 3-72 months). At the last follow-up, the volume of SLA-treated tumors had decreased in 80.6% of patients with follow-up data. Patients with high-grade tumors were more likely to have an unchanged or larger tumor size after SLA treatment than those with low-grade tumors (OR 7.49, p = 0.0364). Subsequent surgery and adjuvant treatment were not required after SLA treatment in 90.4% and 86.7% of patients, respectively. Patients with high-grade tumors were more likely to receive subsequent surgery (OR 2.25, p = 0.4957) and adjuvant treatment (OR 3.77, p = 0.1711) after SLA therapy, without reaching significance. A total of 29 acute complications in 23 patients were reported and included malpositioned catheters (n = 3), intracranial hemorrhages (n = 2), transient neurological deficits (n = 11), permanent neurological deficits (n = 5), symptomatic perilesional edema (n = 2), hydrocephalus (n = 4), and death (n = 2). On long-term follow-up, 3 patients were reported to have worsened neuropsychological test results. Pre-SLA tumor volume, tumor location, number of laser trajectories, and number of lesions created did not result in a significantly increased risk of complications; however, the odds of complications increased by 14% (OR 1.14, p = 0.0159) with every 1-cm3 increase in the volume of the lesion created. CONCLUSIONS: SLA is an effective, minimally invasive treatment option for pediatric brain tumors, although it is not without risks. Limiting the volume of the generated thermal lesion may help decrease the incidence of complications.
OBJECTIVE: This study aimed to assess the safety and efficacy of MR-guided stereotactic laser ablation (SLA) therapy in the treatment of pediatric brain tumors. METHODS: Data from 17 North American centers were retrospectively reviewed. Clinical, technical, and radiographic data for pediatric patients treated with SLA for a diagnosis of brain tumor from 2008 to 2016 were collected and analyzed. RESULTS: A total of 86 patients (mean age 12.2 ± 4.5 years) with 76 low-grade (I or II) and 10 high-grade (III or IV) tumors were included. Tumor location included lobar (38.4%), deep (45.3%), and cerebellar (16.3%) compartments. The mean follow-up time was 24 months (median 18 months, range 3-72 months). At the last follow-up, the volume of SLA-treated tumors had decreased in 80.6% of patients with follow-up data. Patients with high-grade tumors were more likely to have an unchanged or larger tumor size after SLA treatment than those with low-grade tumors (OR 7.49, p = 0.0364). Subsequent surgery and adjuvant treatment were not required after SLA treatment in 90.4% and 86.7% of patients, respectively. Patients with high-grade tumors were more likely to receive subsequent surgery (OR 2.25, p = 0.4957) and adjuvant treatment (OR 3.77, p = 0.1711) after SLA therapy, without reaching significance. A total of 29 acute complications in 23 patients were reported and included malpositioned catheters (n = 3), intracranial hemorrhages (n = 2), transient neurological deficits (n = 11), permanent neurological deficits (n = 5), symptomatic perilesional edema (n = 2), hydrocephalus (n = 4), and death (n = 2). On long-term follow-up, 3 patients were reported to have worsened neuropsychological test results. Pre-SLA tumor volume, tumor location, number of laser trajectories, and number of lesions created did not result in a significantly increased risk of complications; however, the odds of complications increased by 14% (OR 1.14, p = 0.0159) with every 1-cm3 increase in the volume of the lesion created. CONCLUSIONS: SLA is an effective, minimally invasive treatment option for pediatric brain tumors, although it is not without risks. Limiting the volume of the generated thermal lesion may help decrease the incidence of complications.
Authors: Nitesh V Patel; Matthew Mian; R Jason Stafford; Brian V Nahed; Jon T Willie; Robert E Gross; Shabbar F Danish Journal: Neurosurgery Date: 2016-12 Impact factor: 4.654
Authors: Islam Fayed; Matthew F Sacino; Willilam D Gaillard; Robert F Keating; Chima O Oluigbo Journal: Pediatr Neurosurg Date: 2018-08-15 Impact factor: 1.162
Authors: Vivek B Beechar; Sujit S Prabhu; Dhiego Bastos; Jeffrey S Weinberg; R Jason Stafford; David Fuentes; Kenneth R Hess; Ganesh Rao Journal: J Neurooncol Date: 2017-12-04 Impact factor: 4.130
Authors: Eric Prince; Shahin Hakimian; Andrew L Ko; Jeffrey G Ojemann; Michelle S Kim; John W Miller Journal: Curr Neurol Neurosci Rep Date: 2017-09 Impact factor: 5.081
Authors: Alexandre Carpentier; Roger J McNichols; R Jason Stafford; Jean-Pierre Guichard; Daniel Reizine; Suzette Delaloge; Eric Vicaut; Didier Payen; Ashok Gowda; Bernard George Journal: Lasers Surg Med Date: 2011-11-22 Impact factor: 4.025
Authors: Tafadzwa L Chaunzwa; Di Deng; Eric C Leuthardt; Stephen B Tatter; Alireda M Mohammadi; Gene H Barnett; Veronica L Chiang Journal: Neurosurgery Date: 2018-01-01 Impact factor: 4.654
Authors: Manmeet Ahluwalia; Gene H Barnett; Di Deng; Stephen B Tatter; Adrian W Laxton; Alireza M Mohammadi; Eric Leuthardt; Roukoz Chamoun; Kevin Judy; Anthony Asher; Marco Essig; Jorg Dietrich; Veronica L Chiang Journal: J Neurosurg Date: 2018-05-04 Impact factor: 5.115
Authors: Ashwin A Kamath; Daniel D Friedman; Carl D Hacker; Matthew D Smyth; David D Limbrick; Albert H Kim; Ammar H Hawasli; Eric C Leuthardt Journal: Stereotact Funct Neurosurg Date: 2018-01-17 Impact factor: 1.875
Authors: Philip J O'Halloran; Jack Henry; Michael Amoo; Aristotelis Kalyvas; Nilesh Mohan; Gelareh Zadeh; Suneil K Kalia; Paul N Kongkham Journal: World Neurosurg X Date: 2022-09-09